Key result
Evinacumab cuts LDL-C by ~49% versus placebo in patients with HoFH.
Why the study?
Does evinacumab reduce LDL cholesterol levels in patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy?
Does evinacumab reduce LDL cholesterol levels in patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy?
Evinacumab significantly reduces LDL cholesterol levels in patients with homozygous familial hypercholesterolemia already on maximum lipid-lowering therapy.
Supports evinacumab addition in HoFH on maximal therapy; extends RCT evidence for LDL reduction in this population.
In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as compared with the small increase in the placebo group, resulted in a between-group difference of 49.0 percentage points at 24 weeks. (Funded by Regeneron Pharmaceuticals; ELIPSE HoFH ClinicalTrials.gov number, NCT03399786.).
No takes yet. Share an insight, caveat, or question.
Raal et al. (2020) studied this question. Evinacumab reduced LDL cholesterol levels by 49.0 percentage points compared to a small increase in the placebo group at 24 weeks in patients with homozygous familial hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: